NEW YORK (GenomeWeb News) – Invitrogen said today it will continue to screen kinase inhibitors for Chroma Therapeutics after the companies extended an earlier agreement.
Invitrogen will use its SelectScreen service at its facility in Paisley, Scotland, to screen targets, study phylogenetic diversity, and explore signaling pathways to help Chroma Therapeutics “rapidly confirm the selectivity and potency of our small-molecule drugs,” Chroma Therapeutics CSO Alan Drummond said in a statement.
Drummond said Invitrogen’s kinases allow his company to determine if drug candidates are inhibiting the targeted kinases and how they interact with other kinases, and to predict potential side effects.
The agreement extends an earlier one between the companies that has been ongoing for over a year.
Financial terms of the agreement were not released.